Opioid distributors ignored suspicious orders while fueling addiction epidemic

Editorial: The Opioid Distributors Who Watched and Did Nothing

Millions of pills flowed into communities that didn't need them. Small-town pharmacies received shipments ten times larger than their patient populations could justify. Yet the companies responsible for stopping this flow—McKesson, Cardinal Health, and AmerisourceBergen—continued filling orders they knew were suspicious.

For years, the claim that major pharmaceutical distributors ignored obvious red flags while fueling the addiction epidemic sounded like the work of a few bad actors. Industry representatives dismissed the allegations as overblown, arguing they had systems in place to catch diversion. Regulators seemed content with this explanation. The narrative held: maybe some individual employees made mistakes, but the system worked as intended.

The evidence told a different story entirely.

Federal investigations and legal discovery revealed what critics had been saying all along: the three largest opioid distributors in America willfully neglected their legal obligations to report and halt suspicious orders. Internal documents showed they received alerts about impossible quantities of pills going to single locations, yet continued shipping anyway. They knew. That's the part that matters most.

In 2023, McKesson, Cardinal Health, and AmerisourceBergen finalized a landmark $26 billion settlement with state and local governments, effectively admitting fault without admitting guilt—a legal strategy common enough to be almost transparent. The settlement amount itself served as an admission: companies don't pay tens of billions unless they genuinely broke something.

The verification came through specific evidence. Investigators found that these distributors shipped 76 billion opioid pills across America between 2006 and 2012 alone. Some counties received shipments that equaled dozens of pills per resident. Pharmacy chains known as "pill mills" received successive shipments despite zero legitimate medical justification. The distributors had contractual obligations to halt suspicious orders. They had the technology to flag anomalies. They had the legal framework requiring action. What they lacked was the will to disrupt their profit machine.